General Biologicals Corp (GBC, 普生) yesterday said it is near its break-even point, having secured three foreign contracts to supply medical diagnostic testing kits.
The three contracts, valued at about 10 percent of the company’s annual top line, are expected to provide the company with steady revenue over the next two years, GBC president Frank Lin (林孟德) said at a news conference yesterday.
The company makes testing kits for hepatitis A, B, C and D, as well as HIV, which are sold to blood banks and medical institutions across the globe, in addition to in vitro companion diagnostic devices and services.
The company’s efforts at cost optimization have begun to pay off, which led to an improvement in profitability during the first half of this year, Lin said.
Gross margins rose from last year’s 43.11 percent to 51.25 percent at the end of June, he added.
The company’s hepatitis D testing kit has a lot of room to grow as it has just received regulatory approval in Taiwan in January, he said.
While hepatitis D remains the rarest of liver diseases, physicians often recommend hepatitis B patients to undergo National Health Insurance-covered hepatitis D screening to prevent further disease progression.
GBC is also expecting growth for its oral and feminine care products based on the P113 anti-microbial peptide.
The company has continued to expand sales channels for its own-brand oral care products, as well as higher revenue contribution from its original design manufacturing partnerships with Chlitina Holding Ltd (麗豐), which makes and sells beauty and cosmetic products through its salon franchise in Taiwan and China.
The company last reported that revenue during the first half rose 27.32 percent to NT$158 million (US$5.13 million), while gross profit surged 73.94 percent annually to NT$63.07 million.
Cumulative losses were NT$22 million at the end of June.
GBC this month gained the Ministry of Economic Affairs support to hold an initial public offering for its move from the Emerging Stock Board to the Taipei Exchange next year.
POOR INTERNAL CONTROLS: Insurance Bureau Director-General Shih Chiung-hwa said the company is expected to get back on track while its chairman is suspended The Financial Supervisory Commission (FSC) yesterday fined Shin Kong Life Insurance Co (新光人壽) NT$27.6 million (US$939,415) for a reckless investment that endangered its solvency, and suspended its chairman Eugene Wu (吳東進) for poor supervision. The penalty is the second-highest in a single case after Nan Shan Life Insurance Co (南山人壽) was fined NT$30 million in September last year and its chairman Du Ying-tzyong (杜英宗) suspended for two years, the commission said. In three rounds of special and regular examinations conducted since last year, the commission found that Shin Kong Life had given too much power to an asset and liability management committee
Nano-X Imaging Ltd, a start-up founded by Israeli investor Ran Poliakine, is joining forces with South Korean chipmaker SK Hynix Inc to build a machine that could disrupt a century-old X-ray industry. Valued at about US$2 billion after listing on the NASDAQ last month, Nano-X is seeking to transform a multibillion-dollar industry that has essentially relied on the same technology since Nobel Prize in Physics winner Wilhelm Roentgen discovered X-rays in the late 19th century. Nano-X’s device uses semiconductors instead of metal filaments to generate X-rays. The backing of SK Hynix, the world’s second-largest maker of memory chips, is a boost for
Continental AG, which makes control units for Daimler AG cars, cannot pursue antitrust claims against a group of patent owners, including Qualcomm Inc, which are seeking royalties on telecommunications technology, a federal judge in Texas ruled. Avanci LLC, a licensing pool formed by Qualcomm, Nokia Oyj, Sharp Corp and other owners of patents on technology standards, is not breaching antitrust laws when it negotiates license agreements with automakers rather than the component makers, Barbara Lynn, chief district judge for the Northern District of Texas, said in dismissing the suit in a decision posted on Friday. The licensing group charges US$15 per vehicle
Sony Corp has cut its estimated Play Station 5 (PS5) production for this fiscal year by 4 million units, down to about 11 million, following production issues with its custom-designed system-on-chip (SOC) for the new console, people familiar with the matter said. The Tokyo-based electronics giant in July boosted orders with suppliers in anticipation of heightened demand for gaming in the holiday season and beyond, as people spend more time at home due to the COVID-19 pandemic. However, the company has come up against manufacturing issues, such as production yields as low as 50 percent for its SOC, which have cut into